A catheter including an outer conduit and an inner conduit positioned within the outer conduit, the inner conduit having a smaller diameter that that of the outer conduit. A volume between the outer conduit and the inner conduit define a first lumen which may deliver a first fluid to a patient, and an inside diameter of the inner conduit defines a second lumen which may deliver a second fluid to the patient such that the fluid flow of the first fluid and the second fluid exiting the catheter has a flow profile where the first fluid surrounds the second fluid and the second fluid is prevented from contact with inner walls of a blood vessel of the patient in a vicinity of a tip of the catheter.

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 to 40,000 with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 to 40,000 with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.

Apparatus for providing intrabronchial delivery of neurotoxins to control the effects of asthma comprises a shaft having proximal and distal ends and a neurotoxin applicator assembly disposed on the distal end. The neurotoxin applicator assembly comprises a deployable needle assembly, a rotating needle assembly, and a needle-less injection assembly or a nebulizer assembly.

The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.

The present invention relates a botulinum toxin prefilled syringe system with desirable injection force characteristics, in particular low gliding force and low break loose force, comprising a syringe barrel of glass containing a liquid botulinum toxin composition, a plunger stopper and a closure device such as a tip cap or a needle shield. In addition, the present invention relates to a kit comprising the botulinum toxin prefilled syringe system, and optionally instructions for use, and to the use of the botulinum toxin prefilled syringe system in therapeutic and cosmetic applications.

Methods, systems, and devices for the delivery of a therapeutic using a catheter are provided. Many embodiments are directed to a catheter with one or more lumens that can be used to deliver a therapeutic to a tumor. Many embodiments include an occlusion mechanism that can block off downstream vasculature to prevent damage to normal or healthy tissue caused by the therapeutic. Numerous embodiments are used to deliver a bolus of Yttrium-90 microspheres to a tumor. Also provided are methods of using such catheters.

The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

An apparatus and method for inactivating infectious organisms in human body are provided. The apparatus comprises a body having an elongated balloon shape with an open end; a disinfectant containing chlorine dioxide accepted in the body; and an activation module coupled to the body, the activation module includes a case having an opening capable of accommodating the body, an energy supply unit for supplying energy to the disinfectant to activate the chlorine dioxide and a controller for controlling the energy supply unit. The method comprises the steps of inserting the device into a vagina and controlling a degree of activation of the chlorine dioxide to inactive infectious organisms in the vagina by adjusting an intensity of the energy.

A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis involved impregnating an absorbent tip of an applicator with the formulation, the applicator having a rigid rod having the absorbent tip at a distal end thereof, and inserting the applicator straight into a nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip.